Arcellx, Inc.

Human Genome Sciences, Inc.

Subdomain, LLC

Zyngenia, Inc.

Galactica Pharmaceuticals, Inc.

Washington University

Medimmune Limited

Aeres Biomedical, Ltd.

Zygenia, Inc.

Cambridge Antibody Technology Limited

David M Hilbert

David William Lafleur

Steven M Ruben

Tristan J Vaughan

Gil H Choi

Jeffrey S Swers

Viktor Roschke

Peter Kiener

Gregory T Bleck

Steven C Barash

David Lafleur

David Gareth Williams

Daniel P Bednarik

Robert D Schreiber

David M Parmelee

Tarran Jones

Bernadetta Nardelli

Marianne Murphy

Ann Gronowski

David G Williams

D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.

D-domain containing polypeptides and uses thereof

Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.

De novo binding domain containing polypeptides and uses thereof

Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo. In some embodiments, the CAR cell comprises a genetic modification to reduce or eliminate the expression of a targeted antigenic determinant.

Multifunctional immune cell therapies

Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described.

Multivalent and monovalent multispecific complexes and their uses

EGFR-binding modular recognition domains (MRDs) and complexes containing such MRDs linked to antibodies are described. The use of such MRDs and complexes are also described.

EGFR-binding modular recognition domains

Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.

Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides

Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof

The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycatio&#x3c0; endproducts receptor (RAGE).

Nucleic acids encoding rage fusion proteins

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Antibodies that immunospecifically bind to B lymphocyte stimulator protein

Growing community of inventors

Bethesda, MD, United States of America

David M Hilbert